Quarterly report, published
State of Peptides, 2026 Q3
47 of the 82 peptides we track are not FDA approved, and 57% of those have no randomized human trial. This report measures the peptide landscape from our open dataset of 82 peptides, 50 state records, and 31 cost records, plus public FDA adverse event data. Every figure is computed from the data you can download below.
By the PeptideAgent Editorial Team. Draft, pending editorial review.
What are the key findings?
- 57%of the 47 tracked peptides without an FDA approval have no randomized human trial behind them (27 peptides).
- 35 of 82tracked peptides are FDA approved. The most common status among the rest is "unscheduled" (17 peptides).
- 51%of tracked peptides are prohibited in sport under the WADA list in force (42 of 82).
- 12dated regulatory actions on tracked peptides in 2026 so far, 7 of them in the third quarter.
- 34 of 94price channels in our cost data have a dated public source and a published price, covering 12 peptides.
- 12,083 to 98,396sum of per-drug FAERS report counts for the FDA-approved GLP-1 and incretin peptides, 2016 versus 2025 (a report naming two of these drugs counts twice). Report counts are not incidence rates.
- 17 of 50states allow asynchronous telehealth prescribing; 5 do not, and in 28 the state rules we checked do not address it.
1. Where does each peptide stand with regulators?
Each peptide record carries one United States regulatory status and one WADA status, both sourced on the peptide page. The status rules are defined on the methodology page.
Show the data table
| Status | Peptides | Share |
|---|---|---|
| FDA approved | 35 | 43% |
| 503A bulks list | 0 | 0% |
| Under FDA review | 9 | 11% |
| Removed from Category 2 (Apr 2026) | 10 | 12% |
| Not eligible for compounding | 10 | 12% |
| Unscheduled | 17 | 21% |
| Regulatory status unknown | 1 | 1% |
Embed this chart
Show the data table
| WADA status | Peptides | Share |
|---|---|---|
| WADA prohibited | 42 | 51% |
| Not WADA prohibited | 29 | 35% |
| WADA status unclear | 11 | 13% |
Embed this chart
Compounding status of peptides without an FDA approval
| Status | Peptides | Share |
|---|---|---|
| 503A bulks list | 0 | 0% |
| Under FDA review | 9 | 19% |
| Removed from Category 2 (Apr 2026) | 10 | 21% |
| Not eligible for compounding | 10 | 21% |
| Unscheduled | 17 | 36% |
| Regulatory status unknown | 1 | 2% |
Regulatory actions in 2026
12 dated actions affecting tracked peptides so far this year, 7 in the third quarter. Each links to its primary source; the full history is on the regulatory tracker.
- WADA
WADA 2026 Prohibited List takes effect
The 2026 WADA Prohibited List took effect on January 1, 2026 and continues to prohibit the S2 peptide hormone and growth factor classes (GHRH analogs, growth hormone secretagogues, GH fragments, IGF-1 and analogs, MGF, thymosin beta-4 and derivatives, hCG and GnRH-class releasing factors in males), myostatin inhibitors, insulin and the AMPK activator MOTS-c under S4, desmopressin under S5, and BPC-157 under S0. GLP-1 receptor agonists such as semaglutide and tirzepatide are not on the list.
Affects:TesamorelinSermorelinCJC-1295IpamorelinGHRP-2GHRP-6HexarelinMK-677 (ibutamoren)AOD-9604IGF-1 LR3PEG-MGFTB-500 (thymosin beta-4)HCG (human chorionic gonadotropin)GonadorelinKisspeptin-10ACE-031 (ramatercept)InsulinDesmopressinBPC-157MOTS-c
- FDA
FDA approves Imcivree (setmelanotide) for acquired hypothalamic obesity
FDA extended Imcivree to acquired hypothalamic obesity in adults and children 4 years and older, based on the phase 3 TRANSCEND trial.
Regulatory: FDA approvedSource: Manufacturer press release: FDA approval of Imcivree for acquired hypothalamic obesity (March 19, 2026)Affects:Setmelanotide
- FDA
FDA approves a 7.2 mg Wegovy dose for chronic weight management
FDA approved a higher 7.2 mg dose of Wegovy (semaglutide) injection, marketed as Wegovy HD, for weight loss and long-term maintenance of weight loss in certain adults.
Regulatory: FDA approvedSource: FDA press release: FDA approves fourth product under national priority voucher program, higher dose semaglutide (March 19, 2026)Affects:Semaglutide
- FDA
FDA lists BPC-157 and 16 other peptides as withdrawn from 503A Category 2
FDA's Category 2 page, revised in April 2026 and current as of April 22, 2026, moved BPC-157, AOD-9604, CJC-1295, dihexa, DSIP, epitalon, injectable GHK-Cu, ipamorelin, KPV, LL-37, melanotan II, MOTS-c, PEG-MGF, selank, semax, thymosin alpha-1, and thymosin beta-4 fragment (TB-500) to a list of bulk drug substances nominated but withdrawn by their nominators. A withdrawn substance is no longer in 503A Category 2, but withdrawal is not an approval and does not place a substance on the 503A bulks list; a 503A pharmacy still needs a listing before it may compound it. Ipamorelin acetate remains in 503B Category 2. Seven of the withdrawn peptides (BPC-157, KPV, TB-500, MOTS-c, semax, epitalon, and DSIP) were taken to the Pharmacy Compounding Advisory Committee in July 2026.
Regulatory: Removed from Category 2 (Apr 2026)Source: FDA: Certain bulk drug substances for use in compounding may present significant safety risks (503A and 503B Category 2 lists and withdrawn nominations, content current as of April 22, 2026)Affects:BPC-157AOD-9604CJC-1295DihexaDSIP (delta sleep-inducing peptide)EpitalonGHK-CuIpamorelinKPVLL-37Melanotan IIMOTS-cPEG-MGFSelankSemaxThymosin alpha-1TB-500 (thymosin beta-4)
- FDA
FDA proposes to keep semaglutide, tirzepatide and liraglutide off the 503B bulks list
FDA proposed not to include semaglutide, tirzepatide or liraglutide on the 503B bulks list, after tentatively finding no clinical need for outsourcing facilities to compound them from bulk. The notice was published May 1, 2026, and the comment period was extended to July 30, 2026. The proposal was not final as of September 2026. It does not change the 503A rules for patient specific compounding.
- PCAC
PCAC recommends six peptides for the 503A bulks list
At its July 23 to 24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted to recommend that BPC-157, KPV, TB-500, MOTS-c, semax, and epitalon be added to the 503A bulk drug substances list. A committee recommendation is advisory; FDA must still issue a rule before the substances are formally listed.
Regulatory: Under FDA reviewSource: Pharmacy Compounding Advisory CommitteeAffects:BPC-157KPVTB-500 (thymosin beta-4)MOTS-cSemaxEpitalon
- PCAC
PCAC votes against adding DSIP to the 503A bulks list
At the July 23 to 24, 2026 meeting, the Pharmacy Compounding Advisory Committee did not recommend delta sleep-inducing peptide (DSIP) for the 503A bulks list, citing the state of the evidence. FDA makes the final determination by rulemaking.
Regulatory: Not eligible for compoundingSource: Pharmacy Compounding Advisory Committee - Other
Louisiana Act 374 on peptide compounding takes effect
Louisiana Act 374 of 2026 (Senate Bill 253, La. R.S. 37:23.5), signed May 22, 2026, took effect August 1, 2026. It bars Louisiana licensing boards from prohibiting prescribers from providing peptides made by 503A pharmacies or 503B outsourcing facilities that comply with federal compounding law, and from prohibiting Louisiana pharmacists from compounding peptides in compliance with section 503A. It does not make any peptide eligible for 503A or 503B compounding.
- State board
Mississippi medical, nursing, and pharmacy boards bar research-grade peptides
The Mississippi State Board of Medical Licensure, Board of Nursing, and Board of Pharmacy jointly stated that no healthcare provider may compound, administer, dispense, prescribe, advise on, recommend, or supply a non-FDA-approved or research-grade peptide, that consent forms do not remove liability, and that all prescription products and ingredients must come from Board of Pharmacy permitted entities.
- FDA
FDA approves Mounjaro to reduce cardiovascular risk in adults with type 2 diabetes
FDA added an indication for Mounjaro to lower the risk of major adverse cardiovascular events (cardiovascular death, non-fatal heart attack, or non-fatal stroke) in adults with type 2 diabetes who are at high risk for these events. The approval rests on SURPASS-CVOT, in which tirzepatide was non-inferior to dulaglutide (hazard ratio 0.92, 95.3% CI 0.83 to 1.01) but did not show superiority.
Regulatory: FDA approvedSource: Manufacturer press release: FDA approves Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes (August 28, 2026)Affects:Tirzepatide
- FDA
FDA warning letter treats GLP-1 plus vitamin combinations as essentially copies
In a warning letter dated September 18, 2026 and posted September 22, FDA said compounded tirzepatide with niacinamide and semaglutide with cyanocobalamin (vitamin B12) appeared to be essentially copies of approved drugs, that the volume produced suggested the claimed differences were a pretext, and that significant-difference statements were repeated verbatim across many records or chosen from preset menus on prescribing platforms. The letter's findings are specific to one pharmacy, but they apply FDA's April 1, 2026 policy that a combination within 10% of approved strengths by the same route may be treated as essentially a copy without a documented prescriber determination.
Affects:SemaglutideTirzepatide
- WADA
WADA publishes the 2027 Prohibited List
WADA published the 2027 Prohibited List on September 21, 2026, and it takes effect January 1, 2027. The S2 peptide hormone and growth factor classes are unchanged. BPC-157 is still named under S0, and MOTS-c is still named under S4.4 as an activator of AMP-activated protein kinase. WADA added a note that many peptides without approval for human use fall under S0 or another section, and that a peptide not named on the list may still be prohibited. GLP-1 receptor agonists such as semaglutide and tirzepatide are still not on the list.
Affects:TesamorelinSermorelinCJC-1295IpamorelinGHRP-2GHRP-6HexarelinMK-677 (ibutamoren)AOD-9604IGF-1 LR3PEG-MGFTB-500 (thymosin beta-4)HCG (human chorionic gonadotropin)GonadorelinKisspeptin-10ACE-031 (ramatercept)InsulinDesmopressinBPC-157MOTS-c
2. How strong is the evidence, by cluster?
Each peptide's evidence grade, defined on the methodology page, is cited to its studies on the peptide page. Across all 82 peptides, 29 (35%) have no randomized human trial. Among the 47 peptides without an FDA approval, 27 (57%) have no randomized human trial.
- Human RCT evidence
- Human observational evidence
- Animal-only evidence
- Anecdotal evidence only
- No published evidence
Show the data table
| Cluster | Human RCT evidence | Human observational evidence | Animal-only evidence | Anecdotal evidence only | No published evidence | Total |
|---|---|---|---|---|---|---|
| Other peptides | 19 | 1 | 0 | 0 | 0 | 20 |
| Metabolic and growth hormone axis | 9 | 3 | 4 | 0 | 0 | 16 |
| GLP-1 and incretin agonists | 9 | 0 | 0 | 0 | 0 | 9 |
| Tissue repair and healing | 2 | 1 | 6 | 0 | 0 | 9 |
| Longevity and mitochondrial | 4 | 1 | 4 | 0 | 0 | 9 |
| Cognitive and neuroprotective | 1 | 3 | 3 | 0 | 0 | 7 |
| Sexual health and reproductive | 5 | 2 | 0 | 0 | 0 | 7 |
| Immune and antimicrobial | 4 | 0 | 1 | 0 | 0 | 5 |
Embed this chart
3. What do peptides cost in cash?
The index includes only cost channels with a dated public source: a manufacturer list or self-pay price, a published cash price, a peer-reviewed price study, or a licensed provider's published price, each with the date it was checked. Of 94 channels across 31 cost records, 34 qualify. Estimates without a dated source are left out rather than averaged in. Channel detail is on each cost page, and GLP-1 prices are compared side by side on the GLP-1 hub.
Dots mark the low and high of each published range; a single dot is a single published figure. Prices per dose, vial, or pen are in the table only, since they are not comparable to monthly prices.
Show the data table
| Peptide | Channel | Price (USD) | Unit | Checked on | Sources |
|---|---|---|---|---|---|
| Dulaglutide | Self-pay through the manufacturer pharmacy | from $389 | per month | 2026-09-27 | [1] |
| Dulaglutide | List price (Trulicity) | $1,007 | per month | 2026-09-27 | [1] [2] |
| Dulaglutide | With insurance | $0 to $25 | per month | 2026-09-27 | [1] [2] |
| Glutathione | Telehealth program | $75 to $100 | per month | 2026-09-22 | [1] [2] [3] [4] |
| Glutathione | In-person clinic | $35 to $50 | per dose | 2026-09-22 | [1] [2] |
| Gonadorelin | Telehealth program | $50 | per vial | 2026-09-22 | [1] [2] [3] |
| Liraglutide | Generic cash price | $112 to $924 | per month | 2026-09-22 | [1] [2] [3] |
| Liraglutide | List price for type 2 diabetes | $544 to $815 | per month | 2026-09-22 | [1] [2] |
| Liraglutide | List price for weight management | $1,349 | per month | 2026-09-22 | [1] [2] [3] |
| Liraglutide | With insurance | from $25 | per month | 2026-09-22 | [1] [2] [3] |
| NAD+ | Telehealth program | $79 to $199 | per month | 2026-09-22 | [1] [2] [3] |
| NAD+ | In-person clinic | $400 to $900 | per dose | 2026-09-22 | [1] [2] |
| Oxytocin | Branded, from a pharmacy | $2 to $4 | per vial | 2026-09-22 | [1] [2] [3] |
| Oxytocin | Telehealth program | $115 to $135 | per month | 2026-09-22 | [1] [2] [3] [4] |
| PT-141 (bremelanotide) | Branded, from a pharmacy | $233 to $239 | per dose | 2026-09-22 | [1] [2] |
| PT-141 (bremelanotide) | Telehealth program | $187 to $224 | per month | 2026-09-22 | [1] [2] |
| PT-141 (bremelanotide) | With insurance | $0 to $25 | per dose | 2026-09-22 | [1] [2] |
| Semaglutide | Self-pay Wegovy and Ozempic | $149 to $499 | per month | 2026-09-22 | [1] [2] [3] [4] |
| Semaglutide | List price (Wegovy, Ozempic, Rybelsus) | $1,028 to $1,349 | per month | 2026-09-22 | [1] [2] [3] [4] |
| Semaglutide | Compounded pharmacy (2024 survey) | $189 to $294 | per month | 2026-09-22 | [1] [2] [3] [4] [5] |
| Semaglutide | Telehealth program | $223 to $548 | per month | 2026-09-22 | [1] [2] |
| Semaglutide | Savings offer for Wegovy with commercial insurance | from $25 | per month | 2026-09-22 | [1] [2] [3] |
| Semaglutide | Medicare GLP-1 Bridge | $50 | per month | 2026-09-22 | [1] [2] [3] |
| Sermorelin | Telehealth program | $105 to $180 | per month | 2026-09-22 | [1] [2] [3] |
| Teriparatide | Generic cash price | $1,036 to $3,214 | per pen | 2026-09-22 | [1] [2] [3] |
| Teriparatide | List price | $4,290 | per pen | 2026-09-22 | [1] [2] |
| Teriparatide | With insurance | from $4 | per month | 2026-09-22 | [1] [2] |
| Tesamorelin | Branded, from a pharmacy | $10,709 | per month | 2026-09-22 | [1] [2] [3] [4] |
| Tirzepatide | Self-pay Zepbound vials and KwikPen | $299 to $699 | per month | 2026-09-22 | [1] [2] [3] |
| Tirzepatide | List price (Zepbound and Mounjaro) | $499 to $1,112 | per month | 2026-09-22 | [1] [2] |
| Tirzepatide | Compounded pharmacy (2024 survey) | $275 to $399 | per month | 2026-09-22 | [1] [2] [3] [4] [5] |
| Tirzepatide | Telehealth program | $373 to $598 | per month | 2026-09-22 | [1] [2] |
| Tirzepatide | Savings card for Zepbound with commercial insurance | from $25 | per month | 2026-09-22 | [1] [2] [3] [4] |
| Tirzepatide | Medicare GLP-1 Bridge | $50 | per month | 2026-09-22 | [1] [2] |
Embed this chart
| Channel | Channels | Median low | Median high | Lowest | Highest |
|---|---|---|---|---|---|
| Branded, from a pharmacy | 10 | $521 | $1,007 | $112 | $10,709 |
| Compounded pharmacy | 2 | $232 | $347 | $189 | $399 |
| Telehealth program | 7 | $115 | $199 | $75 | $598 |
| With insurance | 7 | $25 | $50 | $0 | $50 |
Monthly prices only. Medians use each channel's published low and high separately; a channel with only a floor (such as an insurance copay "as low as") contributes a low only.
4. What do FDA adverse event reports show?
We counted reports in the FDA Adverse Event Reporting System (FAERS, now part of the FDA Adverse Event Monitoring System [2]) that name each of the 35 FDA-approved peptides in the dataset, by the year FDA received them, through the public openFDA API. 34 of them have at least one report; 1 has none in openFDA. The pull ran on 2026-09-22; openFDA data was last updated 2026-07-30.
Read these counts with care. FDA states that a report does not establish that the product caused the event, that reports are not verified, that not every event is reported and many factors influence whether one is, and that the data cannot be used to estimate incidence. [1] So a rise in reports can reflect wider use or more reporting rather than more harm. A report counts here if the peptide appears anywhere in its drug list, as a suspect or a concomitant drug, and one report can list several reactions. The GLP-1 totals in the key findings and the chart below add up each drug's own report count, so a report naming two of these drugs counts twice. Approvals, prices, and state access for these drugs are on the GLP-1 hub.
Tirzepatide160,934 total
Semaglutide100,912 total
Dulaglutide88,461 total
Exenatide84,435 total
Liraglutide53,485 total
Each panel has its own scale. 2026 is partial (lighter bar): openFDA data last updated 2026-07-30. Pulled from openFDA on 2026-09-22.
Show the data table
| Peptide | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 to date | All years |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tirzepatide | 5 | 7 | 4 | 27 | 33 | 35 | 5,052 | 20,809 | 33,080 | 62,395 | 39,486 | 160,934 |
| Semaglutide | 20 | 21 | 1,168 | 1,834 | 3,965 | 5,526 | 8,097 | 11,908 | 19,203 | 27,550 | 21,606 | 100,912 |
| Dulaglutide | 3,897 | 6,243 | 7,446 | 9,365 | 10,746 | 12,654 | 11,182 | 9,545 | 7,304 | 5,898 | 2,483 | 88,461 |
| Exenatide | 3,440 | 3,696 | 3,857 | 4,329 | 4,241 | 2,984 | 1,827 | 1,317 | 1,219 | 335 | 24 | 84,435 |
| Liraglutide | 4,721 | 3,609 | 4,715 | 3,278 | 2,916 | 2,533 | 2,047 | 2,076 | 1,856 | 2,218 | 1,298 | 53,485 |
Embed this chart
| Peptide | 2025 | 2026 to date | All years in openFDA | Most reported reaction |
|---|---|---|---|---|
| Insulin | 33,849 | 15,574 | 516,830 | blood glucose increased (86,382) |
| Tirzepatide | 62,395 | 39,486 | 160,934 | incorrect dose administered (29,676) |
| Teriparatide | 2,121 | 800 | 112,545 | nausea (9,039) |
| Semaglutide | 27,550 | 21,606 | 100,912 | nausea (14,475) |
| Leuprolide | 7,488 | 2,185 | 92,991 | hot flush (11,166) |
| Dulaglutide | 5,898 | 2,483 | 88,461 | nausea (10,444) |
| Exenatide | 335 | 24 | 84,435 | blood glucose increased (18,570) |
| Liraglutide | 2,218 | 1,298 | 53,485 | nausea (7,778) |
| Octreotide | 1,229 | 588 | 35,427 | diarrhoea (5,228) |
| Abaloparatide | 6,318 | 4,561 | 29,291 | headache (5,125) |
| Linaclotide | 2,480 | 1,465 | 27,604 | diarrhoea (5,075) |
| Lanreotide | 1,060 | 427 | 11,978 | diarrhoea (2,066) |
| Desmopressin | 505 | 241 | 8,649 | hyponatraemia (841) |
| Triptorelin | 859 | 420 | 7,246 | off label use (590) |
| Degarelix | 582 | 251 | 5,879 | fatigue (436) |
| Calcitonin | 220 | 82 | 5,627 | drug ineffective (593) |
| Vasopressin | 515 | 220 | 4,741 | drug ineffective (1,367) |
| Glucagon | 426 | 161 | 4,553 | drug ineffective (399) |
| Enfuvirtide | 76 | 35 | 3,750 | depression (555) |
| Tesamorelin | 240 | 147 | 3,517 | product dose omission issue (299) |
| HCG (human chorionic gonadotropin) | 175 | 105 | 3,388 | ovarian hyperstimulation syndrome (809) |
| Oxytocin | 186 | 84 | 3,229 | foetal exposure during pregnancy (460) |
| Pramlintide | 22 | 5 | 3,069 | blood glucose increased (951) |
| Ziconotide | 98 | 41 | 2,716 | pain (389) |
| Ganirelix | 123 | 62 | 1,930 | ovarian hyperstimulation syndrome (393) |
| Vosoritide | 472 | 206 | 1,331 | injection site pain (179) |
| PT-141 (bremelanotide) | 342 | 205 | 1,005 | nausea (432) |
| Cetrorelix | 35 | 23 | 736 | ovarian hyperstimulation syndrome (170) |
| GonadorelinReports mostly name gonadorelin as a GnRH analogue in cancer regimens (most often listed alongside breast and prostate cancer drugs); approved gonadorelin products are discontinued, so these counts do not describe the gonadorelin product. | 104 | 23 | 612 | neutropenia (96) |
| Terlipressin | 55 | 40 | 346 | drug ineffective (41) |
| Cosyntropin | 16 | 11 | 277 | foetal growth restriction (24) |
| Setmelanotide | 133 | 40 | 270 | nausea (77) |
| Melanotan I (afamelanotide) | 5 | 1 | 19 | anaphylactic reaction (4) |
| Secretin | 0 | 0 | 16 | pancreatitis acute (4) |
| SS-31 (elamipretide) | 0 | 0 | 0 | None reported |
Each peptide name links to the exact openFDA query behind its count. Reaction terms are MedDRA preferred terms as reported. Every per-year query URL is in the CSV download.
5. Where can you get a peptide prescription by telehealth?
From our 50 state records, each citing the state's own statute or board rule. Telehealth prescribing is allowed in 50 states. Compounded GLP-1 access by state: limited in 50. 49 state records follow the FDA 503A bulks framework, 1 does not, and 0 are not addressed. The detail for each state is on its legal access page.
- Allowed
- Not allowed
- Not addressed in state rules
Each tile links to that state's access page with the statute or rule cited.
Show the data table
| State | Telehealth prescribing | Asynchronous prescribing | Compounded GLP-1 access | Follows FDA 503A bulks |
|---|---|---|---|---|
| Alabama | Allowed | Allowed | Limited | Yes |
| Alaska | Allowed | Allowed | Limited | Yes |
| Arizona | Allowed | Allowed | Limited | Yes |
| Arkansas | Allowed | Not allowed | Limited | Yes |
| California | Allowed | Allowed | Limited | Yes |
| Colorado | Allowed | Allowed | Limited | Yes |
| Connecticut | Allowed | Allowed | Limited | Yes |
| Delaware | Allowed | Allowed | Limited | Yes |
| Florida | Allowed | Allowed | Limited | Yes |
| Georgia | Allowed | Not allowed | Limited | Yes |
| Hawaii | Allowed | Not addressed | Limited | Yes |
| Idaho | Allowed | Allowed | Limited | Yes |
| Illinois | Allowed | Not addressed | Limited | Yes |
| Indiana | Allowed | Not addressed | Limited | Yes |
| Iowa | Allowed | Allowed | Limited | Yes |
| Kansas | Allowed | Not addressed | Limited | Yes |
| Kentucky | Allowed | Not addressed | Limited | Yes |
| Louisiana | Allowed | Not allowed | Limited | Yes |
| Maine | Allowed | Not addressed | Limited | Yes |
| Maryland | Allowed | Allowed | Limited | Yes |
| Massachusetts | Allowed | Not addressed | Limited | Yes |
| Michigan | Allowed | Not addressed | Limited | Yes |
| Minnesota | Allowed | Not addressed | Limited | Yes |
| Mississippi | Allowed | Not addressed | Limited | Yes |
| Missouri | Allowed | Not addressed | Limited | Yes |
| Montana | Allowed | Not addressed | Limited | Yes |
| Nebraska | Allowed | Not addressed | Limited | Yes |
| Nevada | Allowed | Allowed | Limited | Yes |
| New Hampshire | Allowed | Not addressed | Limited | Yes |
| New Jersey | Allowed | Not allowed | Limited | Yes |
| New Mexico | Allowed | Not addressed | Limited | Yes |
| New York | Allowed | Not addressed | Limited | Yes |
| North Carolina | Allowed | Not addressed | Limited | Yes |
| North Dakota | Allowed | Not addressed | Limited | Yes |
| Ohio | Allowed | Allowed | Limited | Yes |
| Oklahoma | Allowed | Not addressed | Limited | Yes |
| Oregon | Allowed | Not addressed | Limited | Yes |
| Pennsylvania | Allowed | Allowed | Limited | Yes |
| Rhode Island | Allowed | Not addressed | Limited | Yes |
| South Carolina | Allowed | Not addressed | Limited | Yes |
| South Dakota | Allowed | Not addressed | Limited | Yes |
| Tennessee | Allowed | Not addressed | Limited | Yes |
| Texas | Allowed | Allowed | Limited | Yes |
| Utah | Allowed | Not addressed | Limited | Yes |
| Vermont | Allowed | Allowed | Limited | Yes |
| Virginia | Allowed | Allowed | Limited | No |
| Washington | Allowed | Not addressed | Limited | Yes |
| West Virginia | Allowed | Not allowed | Limited | Yes |
| Wisconsin | Allowed | Not addressed | Limited | Yes |
| Wyoming | Allowed | Not addressed | Limited | Yes |
Embed this chart
6. What is still in preparation?
Two parts of the planned report need data we do not yet license, so they are not published and no figures are estimated in their place.
- Search demand by peptide. In preparation. Method: monthly relative search interest for each peptide name and its common aliases, from a licensed search trend source, indexed to each peptide's own 12-month peak and reported as trends, not volumes.
- Consumer survey. In preparation. Method: at least 1,000 United States adults, quota sampled by age, sex, and region through a licensed research panel, on peptide use, sourcing, and attitudes, with the full questionnaire, weighting, and margin of error published alongside the results.
7. Download the data
Every chart and table above is built from these files, licensed CC BY 4.0. Credit "PeptideAgent, State of Peptides, 2026 Q3" with a link to this page.
| File | Contents | Rows |
|---|---|---|
| regulatory-scorecard.csv | Counts and shares of tracked peptides by United States regulatory status, compounding status (peptides without an FDA approval), and WADA status. | 16 |
| regulatory-events-2026.csv | Dated FDA, PCAC, Federal Register, WADA, and state actions in 2026 affecting tracked peptides, with the primary source URL. | 12 |
| evidence-by-cluster.csv | Number of tracked peptides in each cluster at each evidence grade. | 8 |
| price-index.csv | Every cost channel with a dated source and a published price, in United States dollars, with the date checked and source URLs. | 34 |
| faers-reports-by-year.csv | openFDA adverse event report counts by receipt year for each FDA-approved peptide, with the exact query URL for every count. | 385 |
| faers-top-reactions.csv | The ten most frequently reported reaction terms (MedDRA preferred terms) per FDA-approved peptide, all years, with the query URL. | 340 |
| state-access.csv | Telehealth, asynchronous prescribing, compounded GLP-1 access, and 503A bulks alignment for all 50 states, with the pharmacy board. | 50 |
8. How was this made?
- Regulatory, WADA, and evidence figures count the 82 peptide records in the dataset. Every record is currently a draft pending editorial review, and each status cites its primary source on the peptide page.
- The price index counts a channel only when the record gives the date the price was checked, at least one price, and sources that resolve to URLs. The latest check date in the index is 2026-09-27.
- FAERS counts come from a script that queries the openFDA drug event endpoint once per peptide and year, searching the generic name and the United States product names of its approved products, and writes every query URL to a committed file.
- State access figures count the 50 state records; a state where the rules we checked are silent is reported as not addressed, never guessed.
- Figures recompute from the dataset on every deploy, so this page and the CSV files always agree. Corrections: press@peptideagent.ai.
Sources
Cite this page
Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.
- APA style
PeptideAgent. (2026, September 27). State of Peptides, 2026 Q3. https://peptideagent.ai/data/state-of-peptides-2026-q3- HTML link
<a href="https://peptideagent.ai/data/state-of-peptides-2026-q3">State of Peptides, 2026 Q3</a>, PeptideAgent, updated September 27, 2026.
Educational reference, not medical advice. Read the full disclaimer and talk to a licensed provider before starting, stopping, or combining any treatment.